A new study reveals that people with severe obesity face a significantly higher risk of developing 16 chronic health ...

The TRANSCEND trial evaluated the efficacy and safety of setmelanotide for the treatment of acquired hypothalamic obesity.

The prevalence of metabolic dysfunction–associated steatotic liver disease, chronic kidney disease, and obstructive sleep ...

Stifel analysts were bullish on the data, which showed a 16.5% drop in body-mass index among patients with damage to the ...

A group of children and adults with hypothalamic obesity receiving setmelanotide for 1 year had nearly a 20% greater BMI ...